$CRIS
CURIS INC Stock $cris

$cris Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000110820524000010 Filed on February 08, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$2.086M	$2.696M	$10.02M
YoY Change	-9.19%	-6.62%	-1.37%
Cost Of Revenue	$47.00K	$54.00K	$212.0K
YoY Change	95.83%	-23.94%	-17.51%
Gross Profit	$2.039M	$2.642M	$9.811M
YoY Change	-10.29%	-6.18%	-0.95%
Gross Profit Margin	97.75%	98.0%	97.88%
Selling, General & Admin	$4.891M	$4.877M	$18.65M
YoY Change	2.75%	12.63%	-5.09%
% of Gross Profit	239.87%	184.6%	190.06%
Research & Development	$9.617M	$9.964M	$39.50M
YoY Change	5.22%	14.45%	-8.74%
% of Gross Profit	471.65%	377.14%	402.57%
Depreciation & Amortization	$64.00K	$65.00K	$255.0K
YoY Change	0.0%	-29.35%	9.44%
% of Gross Profit	3.14%	2.46%	2.6%
Operating Expenses	$9.617M	$14.84M	$39.50M
YoY Change	5.22%	13.85%	-8.74%
Operating Profit	-$12.47M	-$12.20M	-$48.33M
YoY Change	7.24%	19.36%	-8.84%
Interest Expense	$515.0K	$665.0K	$2.938M
YoY Change	-21.01%	22.69%	162.56%
% of Operating Profit
Other Income/Expense, Net	$593.0K	-$178.0K	$919.0K
YoY Change	772.06%	-89.22%	-125.16%
Pretax Income	-$11.88M	-$11.71M	-$47.41M
YoY Change	2.74%	3.38%	-16.34%
Income Tax
% Of Pretax Income
Net Earnings	-$11.90M	-$11.71M	-$47.40M
YoY Change	2.59%	3.38%	-16.4%
Net Earnings / Revenue	-570.47%	-434.42%	-472.91%
Basic Earnings Per Share	-$2.05		-$8.96
Diluted Earnings Per Share	-$2.05	-$2.03	-$8.96
COMMON SHARES
Basic Shares Outstanding	5.894M shares	5.883M shares	5.293M shares
Diluted Shares Outstanding	5.784M shares		5.293M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$40.72M	$56.33M	$56.33M
YoY Change	-43.25%	-34.21%	-34.21%
Cash & Equivalents	$29.96M	$26.68M	$26.68M
Short-Term Investments	$10.76M	$29.65M	$29.65M
Other Short-Term Assets	$3.192M	$1.780M	$1.780M
YoY Change	-18.92%	-49.45%	-49.45%
Inventory
Prepaid Expenses
Receivables	$2.154M	$2.794M	$2.794M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$46.07M	$60.91M	$60.91M
YoY Change	-40.95%	-33.88%	-33.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$370.0K	$434.0K	$3.490M
YoY Change	-40.8%	-37.01%	-31.43%
Goodwill	$8.982M	$9.000M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.358M	$3.358M	$3.902M
YoY Change	51.53%	66.07%	46.86%
Total Long-Term Assets	$15.96M	$16.37M	$16.37M
YoY Change	-3.48%	-2.12%	-2.12%
TOTAL ASSETS
Total Short-Term Assets	$46.07M	$60.91M	$60.91M
Total Long-Term Assets	$15.96M	$16.37M	$16.37M
Total Assets	$62.02M	$77.28M	$77.28M
YoY Change	-34.4%	-29.0%	-29.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.628M	$3.172M	$3.172M
YoY Change	37.32%	-0.66%	-0.66%
Accrued Expenses	$6.326M	$9.040M	$10.35M
YoY Change	48.99%	59.18%	51.69%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.30M	$13.52M	$13.52M
YoY Change	40.08%	34.99%	34.99%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$41.26M	$44.10M	$44.10M
YoY Change	-17.29%	-15.66%	-15.66%
Total Long-Term Liabilities	$41.26M	$44.10M	$44.10M
YoY Change	-17.29%	-15.66%	-15.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.30M	$13.52M	$13.52M
Total Long-Term Liabilities	$41.26M	$44.10M	$44.10M
Total Liabilities	$52.56M	$57.61M	$57.61M
YoY Change	-9.3%	-7.52%	-7.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.200B	-$1.200B
YoY Change	0.0%	9.09%
Common Stock	$1.217B	$1.216B
YoY Change	1.69%	1.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.462M	$19.67M	$19.67M
YoY Change
Total Liabilities & Shareholders Equity	$62.02M	$77.28M	$77.28M
YoY Change	-34.4%	-29.0%	-29.0%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$11.90M	-$11.71M	-$47.40M
YoY Change	2.59%	3.38%	-16.4%
Depreciation, Depletion And Amortization	$64.00K	$65.00K	$255.0K
YoY Change	0.0%	-29.35%	9.44%
Cash From Operating Activities	-$13.20M	-$10.18M	-$38.40M
YoY Change	8.2%	-16.99%	-29.28%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$18.91M	$14.52M	$37.79M
YoY Change	-27.93%	319.17%	13.0%
Cash From Investing Activities	$18.91M	$14.52M	$37.79M
YoY Change	-27.93%	319.17%	14.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$14.12M
YoY Change			152.36%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$2.406M	-2.120M	$7.580M
YoY Change	19.94%	52.74%	774.28%
NET CHANGE
Cash From Operating Activities	-$13.20M	-10.18M	-$38.40M
Cash From Investing Activities	$18.91M	14.52M	$37.79M
Cash From Financing Activities	-$2.406M	-2.120M	$7.580M
Net Change In Cash	$3.275M	2.212M	$6.932M
YoY Change	-72.79%	-121.7%	-133.9%
FREE CASH FLOW
Cash From Operating Activities	-$13.20M	-$10.18M	-$38.40M
Capital Expenditures		$0.00	$0.00
Free Cash Flow		-$10.18M	-$38.40M
YoY Change		-16.99%	-29.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-48332000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-53020000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	38000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5679000	usd
CY2023	dei	Entity File Number EntityFileNumber	000-30347
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001108205
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.05
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity Registrant Name EntityRegistrantName	CURIS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3505116
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	128 Spring Street, Building C - Suite 500
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	82300000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5894085	shares
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26681000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19658000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	29653000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	65965000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2794000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2975000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1780000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3521000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	60908000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	92119000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	434000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	689000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	544000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	635000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3056000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4401000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3358000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3358000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2022000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	8982000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	8982000	usd
CY2023Q4	us-gaap	Assets Assets	77282000	usd
CY2022Q4	us-gaap	Assets Assets	108848000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3172000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3193000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9040000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5679000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1305000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1141000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13517000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10013000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1489000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2800000	usd
CY2023Q4	cris	Royalty Guarantees Commitments Amount Noncurrent RoyaltyGuaranteesCommitmentsAmountNoncurrent	42606000	usd
CY2022Q4	cris	Royalty Guarantees Commitments Amount Noncurrent RoyaltyGuaranteesCommitmentsAmountNoncurrent	49483000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	57612000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	62296000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	22781250	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5894085	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5894085	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	11390625	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4830464	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4830464	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	59000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	48000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1215792000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1195687000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1196410000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1148997000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	229000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-186000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	19670000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	46552000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	77282000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	108848000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10023000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10162000	usd
CY2023	us-gaap	Royalty Expense RoyaltyExpense	212000	usd
CY2022	us-gaap	Royalty Expense RoyaltyExpense	257000	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	39496000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	43277000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	2938000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1119000	usd
CY2023	cris	Non Cash Imputed Interest Expense NonCashImputedInterestExpense	2019000	usd
CY2022	cris	Non Cash Imputed Interest Expense NonCashImputedInterestExpense	4771000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	919000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3652000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.96
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.96
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-12.14
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-12.14
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5293294	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5293294	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4669626	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4669626	shares
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	415000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-77000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46998000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-56749000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	90707000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	700000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5594000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6752000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	248000	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-77000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-56672000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	46552000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1300000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13814000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6000000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	302000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	415000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-47413000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	19670000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-47413000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-56672000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	255000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	233000	usd
CY2023	cris	Non Cash Lease Expense NonCashLeaseExpense	1344000	usd
CY2022	cris	Non Cash Lease Expense NonCashLeaseExpense	1158000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	6000000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	6752000	usd
CY2023	cris	Non Cash Imputed Interest Expense Net Of Imputed Interest NonCashImputedInterestExpenseNetOfImputedInterest	-340000	usd
CY2022	cris	Non Cash Imputed Interest Expense Net Of Imputed Interest NonCashImputedInterestExpenseNetOfImputedInterest	659000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1059000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-351000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-181000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-249000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-405000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38434000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-54337000	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	70340000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2276000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3340000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3884000	usd
CY2023	cris	Increase Decrease Operating Lease Liability IncreaseDecreaseOperatingLeaseLiability	-1147000	usd
CY2022	cris	Increase Decrease Operating Lease Liability IncreaseDecreaseOperatingLeaseLiability	-907000	usd
CY2023	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	8979000	usd
CY2022	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	2335000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	62000000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	108126000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	95439000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	416000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	37786000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	33023000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14117000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5842000	usd
CY2023	cris	Payments Of Future Royalty Liability Net Of Imputed Interest PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest	6537000	usd
CY2022	cris	Payments Of Future Royalty Liability Net Of Imputed Interest PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest	4975000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7580000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	867000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6932000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20447000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20293000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40740000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27225000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20293000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2359000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	4112000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-191000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.84pt">Nature of Business</span><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Curis, Inc. is a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4. Throughout these consolidated financial statements, Curis, Inc. and its wholly owned subsidiaries are collectively referred to as “the Company,” “Curis,” “we,” “us,” or “our.”</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a collaboration agreement with Genentech Inc. (“Genentech”), a member of the Roche Group, under which Genentech and F. Hoffmann-La Roche Ltd (“Roche”) are commercializing Erivedge® (vismodegib), a first-in-class orally administered small molecule Hedgehog signaling pathway antagonist. Erivedge is approved for the treatment of advanced basal cell carcinoma (“BCC”).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an exclusive collaboration agreement with Aurigene Discovery Technologies Limited (“Aurigene”) for the discovery, development and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology, including emavusertib.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company’s business, including, but not limited to: the Company’s ability to obtain adequate financing to fund its operations; the Company’s ability to continue as a going concern; the Company’s ability to advance and expand its research and development program for emavusertib; the Company’s ability to execute on its overall business strategies; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; the Company’s ability to comply with regulatory requirements; the Company’s ability to obtain and maintain applicable regulatory approvals and commercialize any approved drug candidates; and the ability of the Company and its wholly owned subsidiary, Curis Royalty, LLC (“Curis Royalty”), to satisfy the terms of the royalty interest purchase agreement (the “Oberland Purchase Agreement”) with entities managed by Oberland Capital Management, LLC (the “Purchasers”), and Lind SA LLC (the “Agent”), as collateral agent for the Purchasers.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s future operating results will largely depend on the progress of emavusertib and the magnitude of payments that it may receive and make under its current and potential future collaborations. The results of the Company’s operations have varied and will likely continue to vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidate.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will require substantial funds to maintain its research and development program and support operations. The Company has incurred losses and cash outflows from operations since its inception. The Company had an accumulated deficit of approximately $1.2 billion as of December 31, 2023 and incurred a net loss of $47.4 million and used $38.4 million of cash in operations for the year ended December 31, 2023. The Company expects to continue to generate operating losses in the foreseeable future. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has concluded there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. Based on the Company's $56.3 million of existing cash, cash equivalents and investments at December 31, 2023, recurring losses and cash outflows from operations since inception, an expectation of continuing losses and cash outflows from operations for the foreseeable future and the need to raise additional capital to finance our future operations, the Company concluded it does not have sufficient cash on hand to support current operations within the next 12 months from the date of filing this Annual Report on Form 10-K. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company plans to seek additional funding through a number of potential avenues, including private or public equity financings, collaborations, or other strategic transactions as needed. The Company may not be able to obtain funding on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. The Company’s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of its control and it may be unable to raise financing when needed, or on terms favorable to the Company. If necessary funds are not available, the Company will have to delay, reduce the scope of, or eliminate its development of emavusertib, potentially delaying the time to market for or preventing the marketing of emavusertib, which may have a material adverse effect on the Company’s operations and future prospects.</span></div>
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1200000000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-47400000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38400000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	56300000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt">Use of Estimates and Assumptions</span>The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of revenue, expenses and certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company’s collaboration agreements; the collectability of receivables; and the value of certain investments and liabilities. Actual results may differ from such estimates.
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	500000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	600000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt">Concentrations and Significant Customer Information</span><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, marketable securities, and accounts receivable. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company’s credit risk related to investments is reduced as a result of the Company’s policy to limit the amount invested in any one issue. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations are located entirely within the U.S. The Company's focus is primarily on the development of emavusertib, a small molecule IRK4 inhibitor. The Company's customer, Genentech, accounted for 99% and 100% of the total gross revenues for the years ended December 31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable at December 31, 2023 and December 31, 2022 represents amounts due from royalties earned on sales of Erivedge by Genentech and Roche.</span></div>The Company relies on third parties to manufacture and supply emavusertib. In addition, there are a small number of suppliers for certain raw materials that the Company uses to manufacture emavusertib.
CY2022Q4	us-gaap	Goodwill Goodwill	9000000.0	usd
CY2023Q4	us-gaap	Goodwill Goodwill	9000000.0	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q4	cris	Debt Securities Available For Sale Accrued Interest DebtSecuritiesAvailableForSaleAccruedInterest	100000	usd
CY2022Q4	cris	Debt Securities Available For Sale Accrued Interest DebtSecuritiesAvailableForSaleAccruedInterest	200000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	29654000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	29653000	usd
CY2023	cris	Available For Sale Securities Weighted Average Maturity AvailableForSaleSecuritiesWeightedAverageMaturity	P0Y2M12D
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	66151000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	188000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	65965000	usd
CY2022	cris	Available For Sale Securities Weighted Average Maturity AvailableForSaleSecuritiesWeightedAverageMaturity	P0Y3M18D
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	27400000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2425000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3146000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1991000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2457000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	434000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	689000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	300000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	200000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3701000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3152000	usd
CY2023Q4	cris	Research And Development Costs Current ResearchAndDevelopmentCostsCurrent	4163000	usd
CY2022Q4	cris	Research And Development Costs Current ResearchAndDevelopmentCostsCurrent	1727000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1059000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	762000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	117000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9040000	usd
CY2022	cris	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-200000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10
CY2023Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P6Y
CY2023Q4	cris	Lessee Operating Lease Liability Cash Obligation LesseeOperatingLeaseLiabilityCashObligation	8800000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1500000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3056000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1305000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1141000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1489000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2800000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2794000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3941000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1665000000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1569000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1558000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3070000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1512000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	276000	usd
CY2023	us-gaap	Royalty Expense RoyaltyExpense	200000	usd
CY2022	us-gaap	Royalty Expense RoyaltyExpense	300000	usd
CY2019Q1	cris	Royalty Purchase Agreement Interest Rate RoyaltyPurchaseAgreementInterestRate	0.015
CY2019Q1	cris	Royalty Purchase Agreement Transaction Fees And Closing Costs RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts	600000	usd
CY2021Q4	cris	Royalty Purchase Agreement Liability Carrying Value RoyaltyPurchaseAgreementLiabilityCarryingValue	53798000	usd
CY2022	cris	Royalty Purchase Agreement Issuance Costs Capitalized Amortization RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization	739000	usd
CY2022	cris	Royalty Purchase Agreement Accretion Expense RoyaltyPurchaseAgreementAccretionExpense	4033000	usd
CY2022	cris	Payments Of Future Royalty Liability PaymentsOfFutureRoyaltyLiability	9087000	usd
CY2022Q4	cris	Royalty Purchase Agreement Liability Carrying Value RoyaltyPurchaseAgreementLiabilityCarryingValue	49483000	usd
CY2023	cris	Royalty Purchase Agreement Issuance Costs Capitalized Amortization RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization	-119000	usd
CY2023	cris	Royalty Purchase Agreement Accretion Expense RoyaltyPurchaseAgreementAccretionExpense	2138000	usd
CY2023	cris	Payments Of Future Royalty Liability PaymentsOfFutureRoyaltyLiability	8896000	usd
CY2023Q4	cris	Royalty Purchase Agreement Liability Carrying Value RoyaltyPurchaseAgreementLiabilityCarryingValue	42606000	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	11390625	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	22781250	shares
CY2016Q3	cris	Collaboration Agreement Numberof Programs Licensed CollaborationAgreementNumberofProgramsLicensed	4	program
CY2023	cris	Collaboration Agreement Numberof Programs Licensed CollaborationAgreementNumberofProgramsLicensed	4	program
CY2023	cris	Share Based Compensation Plans ShareBasedCompensationPlans	2	plan
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	683666	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	64.72
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M3D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	284542	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	13.90
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	515	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	13.40
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	126813	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	64.58
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	840880	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	47.58
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M28D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	91000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	450008	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	63.00
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M7D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	840880	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	47.58
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y1M28D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	91000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.70
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	42.80
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	8000000.0	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6000000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	usd
CY2022	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	usd
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	600000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	1067000	usd
CY2023Q4	cris	Deferred Tax Assets Royalty Purchase Agreement DeferredTaxAssetsRoyaltyPurchaseAgreement	11640000	usd
CY2022Q4	cris	Deferred Tax Assets Royalty Purchase Agreement DeferredTaxAssetsRoyaltyPurchaseAgreement	13285000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	700000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.061
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.060
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.037
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.033
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.049
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.044
CY2023	cris	Effective Income Tax Reconciliation Net Operating Loss Expirations EffectiveIncomeTaxReconciliationNetOperatingLossExpirations	-0.063
CY2022	cris	Effective Income Tax Reconciliation Net Operating Loss Expirations EffectiveIncomeTaxReconciliationNetOperatingLossExpirations	-0.032
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.015
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.006
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.025
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.284
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.309
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	91036000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	79827000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	16973000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	15996000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	24983000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	22565000	usd
CY2023Q4	cris	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	5552000	usd
CY2022Q4	cris	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	6449000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	42271000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	41168000	usd
CY2023Q4	cris	Deferred Tax Assets Stock Options DeferredTaxAssetsStockOptions	4857000	usd
CY2022Q4	cris	Deferred Tax Assets Stock Options DeferredTaxAssetsStockOptions	4506000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	973000	usd
CY2023Q4	cris	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	763000	usd
CY2022Q4	cris	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	1072000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	199048000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	185935000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	198212000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	184738000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	836000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1197000	usd
CY2023Q4	cris	Deferred Tax Liabilities Operating Lease Rightof Use Asset DeferredTaxLiabilitiesOperatingLeaseRightofUseAsset	836000	usd
CY2022Q4	cris	Deferred Tax Liabilities Operating Lease Rightof Use Asset DeferredTaxLiabilitiesOperatingLeaseRightofUseAsset	1197000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	836000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1197000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	25000000.0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	22600000	usd
CY2023Q4	cris	Deferred Tax Assets Capitalization Of Section174 Costs DeferredTaxAssetsCapitalizationOfSection174Costs	16900000	usd
CY2022Q4	cris	Deferred Tax Assets Capitalization Of Section174 Costs DeferredTaxAssetsCapitalizationOfSection174Costs	9800000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	198200000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	184700000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	13500000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	17300000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	usd
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	238

Files In Submission

Name	View Source	Status
0001108205-24-000010-index-headers.html	Edgar Link	pending
0001108205-24-000010-index.html	Edgar Link	pending
0001108205-24-000010.txt	Edgar Link	pending
0001108205-24-000010-xbrl.zip	Edgar Link	pending
cris-12312023x10kexx21.htm	Edgar Link	pending
cris-12312023x10kexx231.htm	Edgar Link	pending
cris-12312023x10kexx311.htm	Edgar Link	pending
cris-12312023x10kexx312.htm	Edgar Link	pending
cris-12312023x10kexx321.htm	Edgar Link	pending
cris-12312023x10kexx322.htm	Edgar Link	pending
cris-12312023x10kexx42.htm	Edgar Link	pending
cris-20231231.htm	Edgar Link	pending
cris-20231231.xsd	Edgar Link	pending
curisclawbackpolicy_adopte.htm	Edgar Link	pending
employmentagtzung_amendedx.htm	Edgar Link	pending
exhibit1045amendmentno1tos.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
cris-20231231_def.xml	Edgar Link	unprocessable
cris-20231231_lab.xml	Edgar Link	unprocessable
cris-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cris-20231231_htm.xml	Edgar Link	completed
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cris-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRIS
CURIS INC Stock $cris

2024 Q1 Form 10-K Financial Statement

#000110820524000010 Filed on February 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS CURIS INC Stock $cris

2024 Q1 Form 10-K Financial Statement

#000110820524000010 Filed on February 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS
CURIS INC Stock $cris